One-Pot Synthesis of Novel Substituted Phenyl-1,5-dihydro-2Hbenzo[ 4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine Derivatives as Potent Antimicrobial Agents
Received Date: Jan 01, 2018 / Accepted Date: Jan 22, 2018 / Published Date: Jan 27, 2018
In this paper, we have reported the synthesis of novel substituted phenyl-1,5-dihydro-2H-benzo[4,5] thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine derivatives (4a-m). The title compounds were synthesized by the reaction of substituted 2-aminobenzothiazole, barbituric/thiobarbituric acid and substituted benzaldehydes using 2-3 drops of HCl in ethanol. The synthesized compounds were evaluated for their antimicrobial efficiency against various microbial strains at different concentrations. Among the tested compounds, the compounds 4k and 4j were found to be more active against all the tested pathogens. Additionally, selected compounds were screened for in silico molecular docking studies.
Keywords: Condensation; Pyrimidine; Antimicrobial activity; Molecular docking study
Multicomponent reactions (MCR) play an important role in organic, combinatorial and medicinal chemistry  as it furnishes products with a high degree of chemical and structural variability. Their productivity and the simplicity of reaction techniques make MCRs inexpensive, less time-consuming and ecofriendly in comparison to conventional multistep synthesis [2,3]. The exploitation of a simple molecule with various functionalities for the synthesis of bio heterocycles is a useful contribution in the heterocyclic chemistry . Recently, the chemistry and biological outlines of several pharmacophores of 2-substituted benzothiazole products have been addressed [5,6]. The effect of substituents on the benzothiazole ring displayed accompanying structure-activity relationship . Furthermore, benzothiazole derivatives are essential scaffolds in drug design associated with broad verities of medicinal uses . On the other hand, pyrimidine is also a familiar class of heterocyclic compound possessing a wide range of biological activities and their importance in medicine is very much recognized . Several pyrimidine derivatives have exhibited efficiency in fighting various diseases and observed to use as good beneficial agents such as antibacterial , antifungal , anti-tumor  and anti-HIV agents .
Encouraged by the above results, in this paper we have reported the synthesis of some novel substituted phenyl-1,5-dihydro-2H-benzo[4,5] thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine derivatives. All the newly synthesized compounds were screened for the in vitro antimicrobial activities. In addition, we described the analysis of potentially active target compounds against DNA Gyrase and CYP51 ligands by comparing the various docked orientations of the molecules.
Materials and methods
All reactions were performed at reflux temperature with stirring, the chemicals were purchased from Merck and solvents were used without further purification. Analytical thin layer chromatography was performed with E. Merck silica gel GF254 glass plates and melting point was determined using thermal analyzer (Shimadzu DS-50). The FTIR spectra were obtained using KBr pellets on Shimadzu spectrometer, the 1H-NMR and 13C-NMR spectrum were recorded on Bruker 400 MHz and 100 MHz respectively in DMSO-d6 as a solvent using tetramethylsilane (TMS) as internal standard. LCMS were obtained using C-18 column on Shimadzu, LCMS 2010A, Japan.
General procedure for synthesis of substituted phenyl-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d] pyrimidine derivatives (4a-m)
The mixture of substituted 2-aminobenzothiazoles (1 mmol), barbituric/thiobarbituric acid (1 mmol), substituted benzaldehydes (1 mmol) and 2-3 drops of HCl in ethanol was refluxed with constant stirring for about 8 h. After completion of the reaction, the reaction mixture was poured into the crushed ice with vigorous stirring and the solid residue separated was filtered, dried and recrystallized using ethanol.
5-(4-Hydroxyphenyl )-1,5-d ihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine-2,4(3H)-dione (4a): Pale yellow; yield 91%; mp 308-310°C; IR (cm-1): 1593, 1666, 2916, 3266, 3431; 1H-NMR (DMSO-d6) δ ppm: 5.89 (s, 1H, N-CH), 6.83-8.28 (m, 8H, Ar-H), 9.44 (s, 1H, Ar-OH), 11.33 (s, 1H, NH), 11.41 (s, 1H, NH); 13C-NMR (DMSO-d6) δ ppm: 61.85, 119.41, 121.78, 123.47, 125.25, 126.06, 126.94, 134.33, 136.54, 147.25, 149.60, 155.05, 157.91, 161.51, 168.52; LCMS: m/z [M+1]: 365.00.
5-(3-Fluorophenyl)-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine-2,4(3H)-dione (4b): Light yellow; yield 88%; mp 262-264°C; IR (cm-1): 752, 1597, 1643, 3249; 1H-NMR (DMSO-d6) δppm: 5.99 (s, 1H, N-CH), 6.15-8.22 (m, 8H, Ar-H), 11.52 (s, 1H, NH), 11.61 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 61.87, 113.10, 118.77, 121.47, 122.94, 124.26, 125.51, 126.02, 126.17, 129.25, 134.01, 136.21, 146.66, 148.92, 157.31, 161.87, 164.92, 166.13; LCMS: m/z [M+1]: 367.00.
5-(3-Nitrophenyl)-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine-2,4(3H)-dione (4c): Dark yellow; yield 90%; mp 300-302°C; IR (cm-1): 1600, 1655, 3215; 1H-NMR (DMSO-d6) δppm: 5.98 (s, 1H, N-CH), 7.79-6.69 (m, 8H, Ar-H), 11.45 (s, 1H, NH), 11.57 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 60.05, 100.12, 119.15, 124.47, 124.56, 126.51, 12.02, 128.17, 129.25, 133.08, 137.01, 147.08, 148.88, 155.34, 157.33, 163.22, 167.12; LCMS: m/z [M+1]: 395.03.
9-Chloro-5-(3-nitrophenyl)-2-thioxo-1,2,3,5-tetrahydro-4Hbenzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidin-4-one (4d): Light brown; yield 88%; mp 293-295°C; IR (cm-1): 782, 1365, 1610, 1640, 3255; 1H-NMR (DMSO-d6) δppm: 5.58 (s, 1H, N-CH), 6.29- 7.82 (m, 7H, Ar-H), 11.62 (s, 1H, NH), 11.71 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 59.55, 102.10, 118.10, 124.40, 124.65, 126.50, 127.82, 128.37, 129.45, 133.18, 137.51, 147.58, 148.62, 154.30, 157.20, 163.02, 167.18; LCMS: m/z [M+1] and [M+2]: 443 and 445.
9-Chloro-5-(3-fluorophenyl)-2-thioxo-1,2,3,5-tetrahydro-4Hbenzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidin-4-one (4e): Light brown; yield 85%; mp 293-295°C; IR (cm-1): 756, 788, 1610, 1667, 3205; 1H-NMR (DMSO-d6) δppm: 5.89 (s, 1H, N-CH), 6.15- 8.28 (m, 7H, Ar-H), 11.50 (s, 1H, NH), 11.61 (s, 1H, NH); 13C-NMR ((DMSO-d6) δppm: 55.85, 98.07, 112.18, 122.47, 123.24, 124.36, 125.21, 126.22, 126.47, 129.22, 135.01, 136.26, 147.18, 148.82, 157.21, 160.82, 164.32, 167.24; LCMS: m/z [M+1] and [M+2]: 416 and 418.
9-Chloro-5-(2,6-difluorophenyl)-2-thioxo-1,2,3,5-tetrahydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidin-4-one (4f): Yellow; yield 83%; mp 256-258°C; IR (cm-1): 756, 788, 1610, 1647, 3205; 1H-NMR (DMSO-d6) δppm: 5.89 (s, 1H, N-CH), 6.15-8.28 (m, 6H, Ar- H), 11.33 (s, 1H, NH), 11.41 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 54.83, 100.04, 111.16, 123.24, 124.36, 125.71, 126.42, 126.36, 132.22, 135.81, 136.86, 147.08, 148.62, 157.31, 161.12, 164.32, 167.24; LCMS: m/z [M+1] and [M+2]: 434.80 and 436.10.
9-Chloro-5-(4-hydroxyphenyl)-2-thioxo-1,2,3,5-tetrahydro-4Hbenzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidin-4-one (4g): Dark orange; yield 90%; mp 310-312°C; IR (cm-1): 785, 1335, 1610, 1641, 3260, 3448; 1H-NMR (DMSO-d6) δppm: 5.30 (s, 1H, N-CH), 6.82-8.27 (m, 7H, Ar-H), 9.53 (s, 1H, OH), 11.33 (s, 1H, NH), 11.41 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 60.05, 96.29, 119.01, 121.88, 123.07, 125.26, 126.16 (2C), 126.96, 134.13, 138.04, 147.35, 149.20, 155.55, 162.23, 157.82, 162.01, 169.02; LCMS: m/z [M+1] and [M+2]: 415.10 and 417.00.
5-(4-Chlorophenyl)-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine-2,4(3H)-dione (4h): Light gray; yield 86%; mp 290-292°C; IR (cm-1): 784, 1605, 1658, 1678, 3218; 1H-NMR (DMSO-d6) δppm: 5.96 (s, 1H, N-CH), 6.84-8.30 (m, 8H, Ar-H), 11.02 (s, 1H, NH), 11.11 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 65.24, 96.00, 113.11, 123.28, 124.10, 127.82, 128.37, 129.45, 134.12, 138.21, 148.18, 149.60, 155.20, 157.25, 162.23, 168.10; LCMS: m/z [M+1] and [M+2]: 383.02 and 385.03.
5-(P-tolyl)-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a] pyrimido[4,5-d]pyrimidine-2,4(3H)-dione (4i): Light white; yield 90%; mp 285-287°C; IR (cm-1): 1610, 1652, 3220; 1H-NMR (DMSO-d6) δppm: 2.43 (s, 3H, CH3), 5.98 (s, 1H, N-CH), 6.80-8.32 (m, 8H, Ar- H), 11.10 (s, 1H, NH), 11.22 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 21.18, 63.28, 95.02, 114.10, 123.15, 124.36, 126.23, 127.30, 128.32, 129.46, 135.10, 138.01, 147.14, 148.90, 155.30, 157.05, 167.18; LCMS: m/z [M+1]: 363.06.
5-Phenyl-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine-2,4(3H)-dione (4j): Light gray; yield 85%; mp 248-250°C; IR (cm-1): 1615, 1720, 1678, 3240; 1H-NMR (DMSO-d6) δppm: 5.93 (s, 1H, N-CH), 6.76-8.30 (m, 9H, Ar-H), 11.12 (s, 1H, NH), 11.20 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 61.20, 94.08, 113.18, 122.10, 123.66, 126.22, 128.62 130.16, 136.12, 139.09, 148.10, 149.50, 156.35, 158.08, 162.23, 168.10; LCMS: m/z [M+1]: 349.06.
5-Phenyl-2-thioxo-1,2,3,5-tetrahydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidin-4-one (4k): Light yellow; yield 88%; mp 276-278°C; IR (cm-1): 1618, 1542, 1644, 3245(NH); 1H-NMR (DMSO-d6) δppm: 5.96 (s, 1H, N-CH), 6.78-8.32 (m, 9H, Ar-H), 11.24 (s, 1H, NH), 11.33 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 65.28, 98.48, 113.25, 123.10, 124.60, 126.23, 128.65, 129.12, 135.13, 138.29, 147.20, 148.20, 157.33, 158.56, 162.22, 168.20; LCMS: m/z [M+1]: 365.40.
2-Thioxo-5-(p-tolyl)-1,2,3,5-tetrahydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidin-4-one (4l): Light yellow; yield 90%; mp 326-328°C; IR (cm-1): 1545, 1620, 1671, 3255; 1H-NMR (DMSO-d6) δppm: 2.43 (s, 3H, CH3), 5.96 (s, 1H, N-CH), 6.78-8.32 (m, 9H, Ar-H), 11.03 (s, 1H, NH), 11.11 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 22.24, 64.25, 95.43, 113.05, 123.36, 124.62. 125.26, 128.86, 130.54, 135.16, 138.23, 147.00, 148.28, 156.96, 158.88, 163.45, 169.24; LCMS: m/z [M+1]: 379.06.
5-(4-Chlorophenyl)-2-thioxo-1,2,3,5-tetrahydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidin-4-one (4m): Pale yellow; yield 88%; mp 288-290°C; IR (cm-1): 785, 1343, 1614, 1658, 3240; 1H-NMR (DMSO-d6) δppm: 5.99 (s, 1H, N-CH), 6.75-8.35 (m, 8H, Ar-H), 11.10 (s, 1H, NH), 11.22 (s, 1H, NH); 13C-NMR (DMSO-d6) δppm: 66.32, 108.23, 112.03, 124.06, 125.02, 126.36, 128.23, 129.04, 133.56, 137.07, 146.05, 147.88, 155.16, 157.54, 163.43, 169.14; LCMS: m/z [M+1] and [M+2]: 398 and 400.01.
The synthesized compounds were screened for in vitro antimicrobial activity against five pathogenic bacterial strains viz., Escherichia coli (MTCC 1559), Pseudomonas syringae (MTCC-1604), Salmonella typhi (MTCC-734), Staphylococcus aureus (MTCC-902) and Xanthomonas campestris (MTCC-2286) and five fungal strains, Alternaria solani (MTCC-2101), Aspergillus flavus (MTCC-277), Fusarium oxysporum (MTCC-284), Candida albicans (MTCC-1637) and Chrysosporium keratinophilum (MTCC-1367).
The in vitro antimicrobial activity was determined by agar well diffusion method . The 10% DMSO was used as a negative control whereas ciprofloxacin was used as standard for antibacterial activity and bavistin for antifungal activity. The Minimum Inhibitory Concentration (MIC) measurements were achieved by using serial broth-dilution method .
In silico molecular docking studies
The structure of synthesized molecules and standards were drawn in Chem Bio Draw tool (Chem Bio Office Ultra 14.0 suite) assigned with proper 2D orientation and structure of each was checked for structural drawing error. Energy of each molecule was minimized using Chem Bio 3D (Chem Bio Office Ultra 14.0 suite). The energy minimized ligand molecules were then used as input for Auto Dock Vina, in order to carry out the docking simulation. The protein data bank (PDB) coordinate file with the name DNA Gyrase and CYP51 was used as receptor molecule in antibacterial and antifungal activity respectively [16,17].
Results And Discussion
In the present study, the synthesis of target compounds was achieved according to the reaction illustrated in the Scheme 1. The novel substituted phenyl-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a] pyrimido[4,5-d]pyrimidine derivatives (4a-m) were synthesized via the one pot three component condensation reaction between 2-amino benzothiazole, barbituric/thiobarbituric acid and substituted benzaldehyde in ethanol using hydrochloric acid as a catalyst at reflux temperature with constant stirring.
The structure of the desired substituted phenyl-1,5-dihydro-2Hbenzo[ 4,5]thiazolo[3,2-a]pyrimido[4,5-d]pyrimidine derivatives (4a-m) were confirmed by IR, NMR and Mass spectral data. The IR spectrum of compound 4a showed broad peak at 3431 cm-1 due to hydroxyl group and another band in the region 3266 cm-1 that corresponded to NH functionality. The absorption bands at 1666 and 1593 cm-1 corresponded C=O and C=N group respectively. The 1H-NMR spectrum of compound 4a exhibited two singlets at δ 11.33 and 11.41 ppm corresponded for two NH protons and another singlet at δ 9.44 ppm which confirmed the presence of OH proton. The multiplet between δ 8.28-6.84 ppm is due to aromatic protons and a singlet at δ 5.89 ppm corresponds to pyrimidine CH proton. Further, 13C-NMR spectrum of compound 4a confirmed the proposed structure by appearance of signal at δ 168.52 ppm due to the C=O carbon and another signal at δ 161.51 ppm correspond to C=N carbon of barbituric acid ring. Another signal at δ 157.91 ppm attributed to C-OH carbon. The mass spectrum of compound 4a showed molecular ion peak [M+] at m/z 365.00 which corresponds to the molecular weight of the compound 4a.
In vitro antimicrobial activity
All the tested samples showed appreciable antibacterial activity against the tested pathogens at 1, 2.5 and 5 mg/mL concentrations. The highest zone of inhibition was observed by compound 4j followed by 4d, 4e and 4k (Table 1).
Conc in mg/mL
|Zone of inhibition in mm|
S.a- Staphylococcus aureus; S.t- Salmonella typhi; P.s- Pseudomonas syringae; X.c- Xanthomonas campestris; E.c- Escherichia coli
Table 1: Antibacterial activity results of synthesized compounds (4a-m).
Similarly, the tested samples were screened for their antifungal activity and they showed appreciable inhibitory activity against the tested pathogens. The compounds 4i, 4e and 4m exhibited remarkable antifungal activity compared to other compounds (Table 2).
|Compound||Zone of inhibition in mm|
A.s- Alternaria solani; A.f- Aspergillus flavus ; F.o- Fusarium oxysporum; C.a- Candida albicans; C.k- Cryzosporium keratinophilum
Table 2: Antifungal activity results of synthesized compounds (4a-m).
The synthesized compounds were also subjected for the MIC study and the results are displayed in Table 3. Among all the compounds, compound 4k and 4j were found to be more effective against E. coli, P. syringae and S. aureus with MIC value of 50 μg/mL. The compounds 4d, 4e, 4f, 4g, 4h, 4i and 4l showed good potencies with MIC value in the range of 75-250 μg/mL against all the bacterial strains.
|Compound||Minimum inhibitory concentration (µg/mL)|
S.a- Staphylococcus aureus; S.t- Salmonella typhi; P.s- Pseudomonas syringae; X.c- Xanthomonas campestris; E.c- Escherichia coli; A.s- Alternaria solani; A.f- Aspergillus flavus; F.o- Fusarium oxysporum; C.a- Candida albicans; C.k- Cryzosporium keratinophilum
Table 3: Minimum antimicrobial concentration of synthesized compounds (4a-m).
Among all the compounds screened for antifungal efficacy, compounds 4j, 4h and 4m were found to have good MIC value of 150 μg/mL against F. oxysporum, A. flavus and A. solani respectively. The compounds 4d, 4e, 4f, 4g, 4i and 4l displayed considerable activity with MIC value in the range of 200-500 μg/mL against all the fungal strains.
The obtained results revealed that, human pathogenic bacteria E. coli, S. aureus and S. typhi were more susceptible to all the tested compounds and these results were in agreement with the findings of Sahu et al. . The plant pathogens viz, A. flavus and F. oxysporum were more susceptible to tested compounds and X. campestris, P. syringae were found to be less susceptible . All the compounds showed appreciable antimicrobial activity and the activity was comparable with the standard drugs ciprofloxacin and bavistin.
In silico molecular docking studies
The docking of receptors DNA Gyrase and CYP51 with synthesized compounds 4c, 4e, 4f, 4g, 4h, 4j and 4k exhibited well-established bonds with amino acids (Asp437, Arg1122, Ser1085, His470, Val312, Lys152, Gly311 and Tyr141 respectively) in the receptor active pocket. The synthesized molecules having 2D structure were converted to energy minimized 3D structures and were further used for in silico protein-ligand docking. Figures 1 and 2 (2D and 3D image) showed the docked images of synthesized molecules including standard drugs ciprofloxacin and bavistin. All the compounds showed appreciating results with encouraging binding energy and exhibited the bonding with one or other amino acids in the active pockets. In silico studies revealed that all the synthesized molecules showed good binding energy with strong affinity towards the target protein DNA Gyrase and CYP51 ranging from -5.1 to -5.9 kcal/mol and -9.0 and -9.6 respectively (Tables 4 and 5).
|Compound||Affinity (kcal/mol)||H-bonds||H-bond length (Å)||H-bond with||Hydrophobic Interactions|
|Asp437, Arg458, Gly459, Ser1084, Phe1123|
|Gly436, Arg458, Gly459, Asp512, Arg1122|
|4f||-5.1||0||-||-||Gly436, Asp437, Asp512, Ser1084, Arg1122, Phe1123|
|Gly436, Arg458, Gly459, Asp512, Ser1084|
|Gly436, Asp437, Gly459, Gly1082, Phe1123|
|Gly436, Asp437, Gly459, Gly1082|
|4k||-5.1||1||3.04||2XCT:Asp437 ::4k:NAD||Arg458, gly459, Ser1084, Phe1123|
|Ciprofloxacin||-4.4||1||3.04||2XCT:Arg1122 :: CIPROFLOXACIN:OAQ||Asp512, Ser1084, Ser1085|
Table 4: Docking results for antibacterial activity of synthesized compounds (4a-m).
|Compound||Affinity (kcal/mol)||H-bonds||H-bond length (Å)||H-bond with||Hydrophobic interactions|
|Phe135, Ile140, Tyr141, Lys152, Phe237, Gly311, Val312, Met314, Gly315, Phe465, Cys472|
|4e||-9.6||0||-||-||Tyr127, Tyr141, Phe242, Leu381, Leu384, Arg386, His 470|
|4f||-10.0||1||3.03||5JLC:Val312::4f:NAE||Thr131, Ile140, Leu148, Lys152, Phe237, Gly311, Gly315, Gly316, Leu381, Ile472, Cys472|
|4g||-9.6||1||3.17||5JLC:Lys152::4g:OBA||Thr131, Phe135, Ile140, Tyr141, Leu148, Val155, Leu159, Val312, Gly315, His470, Cys472, Ile473, Gly474|
|Thr131, Ile140, Tyr141, Leu148, Lys152, Phe237, Gly311, Val312, Gly315, Phe465, Arg471, Cys472|
|Tyr127, Phe135, Ile140, Tyr141, Leu148, Lys 152, Val312, Gly315, His470, Cys472|
|4k||-9.0||1||2.91||5JLC:Tyr141::4k:OAX||Phe114, Tyr127, Gly311, Val312, Gly315, Leu381, Leu384, Arg386, Phe465, His470, Cys472|
|Tyr127, Leu130, Phe242, Leu381, Leu384, Met512|
Table 5: Docking results for antifungal activity of synthesized compounds (4a-m).
In the present investigation, we have reported the synthesis of series of novel substituted phenyl-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a] pyrimido[4,5-d]pyrimidine derivatives (4a-m). The desired compounds were prepared in one pot using three different components with high yields and all the synthesized compounds were screened for the antimicrobial activity. The results showed that most of the derivatives inhibited the growth with higher inhibition zones and it may due to the structural orientation and different substituents. Hence, can be used as effective antimicrobial drugs in future.
The authors are thankful to the Chairman, Department of Industrial Chemistry, Kuvempu University, Shankaraghatta for providing the laboratory facilities and IISc Bangalore for providing spectral data.
- Orru RVA, Greef M (2003) Recent advances in solution-phase multicomponent methodology for the synthesis of heterocyclic compounds. Synthesis 10: 1471-1499.
- Mont N, Teixido J, Borrell J, Kappe CO (2003) A three-component synthesis of pyrido[2,3-d]pyrimidines. Tetrahedron Lett 44: 5385-5387.
- Tandel S, Bliznets I, Ebinger K, Ma YA, Bhumralkarc D, et al. (2004) One-pot syntheses of 6-mercaptopurines(6MP) from 4,5-diamino-6-chloro-pyrimidinesq Tetrahedron Lett 45: 2321-2322.
- Al-Omary FAM, Hassan GS, El-Messery SM, El-Subbagh HI (2012) Substituted thiazoles V. Synthesis and antitumor activity of novel thiazolo[2,3-b]quinazoline and pyrido[4,3-d]thiazolo[3,2-a]pyrimidine analogues. Eur J Med Chem 47: 65-72.
- Yadav PS, Devprakash D, Senthilkumar GP (2011) Benzothiazole: different methods of synthesis and diverse biological activities. Int J Pharm Sci Drug Res 3: 01-07.
- Sompalle R, Roopan SM (2013) Review on benzothiazoles: synthesis and diverse biological activities. Chem Sci Rev Lett 2: 408-414.
- Junjie M, Dong C, Kuan L, Lihui W, Xiaoqi H, et al. (2014) Design, synthesis and structure activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy Ncarbamoylhydrazone moiety as potent antitumor agents. Eur J Med Chem 86: 257-269.
- Quiroga J, Hernandez P, Insuasty B, Abonia R, Cobo J, et al. (2002) Control of the reaction between 2-aminobenzothiazoles and mannich bases: Synthesis of pyrido[2,1-b][1,3]benzothiazoles versus [1,3]benzothiazolo[2,3-b]quinazolines. J Chem Soc Perkin Trans 14: 555-559.
- Brown DJ, Evans RF, Cowden WB (1984) Comprehensive heterocyclic chemistry. UK: Pergamon Press Oxford, 15.
- Venkatesh T. Bodke YD, Joy NM, Vinoda BM, Shiralgi Y, et al. (2016) Synthesis of some novel 5,7-disubstituted-2-phenyl-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidine derivatives and evaluation of their biological activity. Lett Org Chem 13: 661-671.
- Maddila S, Gorle S, Seshadri N, Lavanya P, Jonnalagadd SB (2014) Synthesis, antibacterial and antifungal activity of novel benzothiazole pyrimidine derivatives. Arab J Chem 9: 681-687.
- Hou J, Wan S, Wang G, Zhang T, Li Z, et al. (2016) Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor. Eur J Med Chem 118: 276-289.
- Miazga A, Ziemkowski P, Siwecka MA, Lipniacki A, Piasek A, et al. (2010) Synthesis, biological properties and anti-HIV-1 activity of new pyrimidine P1,P2-dinucleotides. Nucleosides Nucleotides Nucleic Acids 29: 438-444.
- Bondock S, Fadaly W, Metwally MA (2009) Enaminonitrile in heterocyclic synthesis: Synthesis and antimicrobial evaluation of some new pyrazole, isoxazole and pyrimidine derivatives incorporating a benzothiazole moiety. Eur J Med Chem 44: 4813-4818.
- Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS approved standard M7-A9. NCCLS 2012, Wayne, PA.
- Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, et al. (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466: 935-940.
- Vijesh AM, Isloor AM, Sandeep T, Arulmoli T, Hoong-Kun Fun (2013) Molecular docking studies of some new imidazole derivatives for antimicrobial properties. Arab J Chem 6: 197-204.
- Sahu PK, Gupta SK, Thavaselvamd D, Agarwal DD (2012) Synthesis and evaluation of antimicrobial activity of 4H-pyrimido[2,1-b] benzothiazole, pyrazole and benzylidene derivatives of curcumin. Eur J Med Chem 54: 366-378.
- Gilani SJ, Nagarajan K, Dixit SP, Taleuzzaman M, Khan SA (2012) Benzothiazole incorporated thiazolidin-4-ones and azetidin-2-ones derivatives: Synthesis and in vitro antimicrobial evaluation. Arab J Chem 9: 1523-2531.
Citation: Venkatesh T, Bodke YD, Nagaraj K, Kumar SR (2018) One-Pot Synthesis of Novel Substituted Phenyl-1,5-dihydro-2H-benzo[4,5]thiazolo[3,2-a] pyrimido[4,5-d]pyrimidine Derivatives as Potent Antimicrobial Agents. Med Chem (Los Angeles) 8: 001-007. Doi: 10.4172/2161-0444.1000488
Copyright: © 2018 Venkatesh T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
International Conference on Medicinal and Pharmaceutical Chemistry
July 19-21, 2018 Dubai, UAE
International Conference on Medicinal Chemistry & Pharmacology
July 25-26, 2018 Vancouver, Canada
International Conference on Past and Present Research Systems on Green Chemistry
27-28th August, 2018 Boston, USA
World Congress on Green Chemistry and Technology
September 17-19, 2018 Amsterdam, Netherlands
- Total views: 575
- [From(publication date): 0-2018 - Jul 19, 2018]
- Breakdown by view type
- HTML page views: 518
- PDF downloads: 57